EZH2 modifies sunitinib resistance in renal cell carcinoma by kinome reprogramming

Acquired and intrinsic resistance to receptor tyrosine kinase inhibitors (RTKi) represent a major hurdle in improving the management of clear cell renal cell carcinoma (ccRCC). Recent reports suggest that drug resistance is driven by tumor adaptation via epigenetic mechanisms that activate alternati...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:Cancer Res
Main Authors: Adelaiye-Ogala, Remi, Budka, Justin, Damayanti, Nur P., Arrington, Justine, Ferris, Mary, Hsu, Chuan-Chih, Chintala, Sreenivasulu, Orillion, Ashley, Miles, Kiersten Marie, Shen, Li, Elbanna, May, Ciamporcero, Eric, Arisa, Sreevani, Pettazzoni, Piergiorgio, Draetta, Giulio F., Seshadri, Mukund, Hancock, Bradley, Radovich, Milan, Kota, Janaiah, Buck, Michael, Keilhack, Heike, McCarthy, Brian P., Persohn, Scott A., Territo, Paul R., Zang, Yong, Irudayaraj, Joseph, Tao, W. Andy, Hollenhorst, Peter, Pili, Roberto
פורמט: Artigo
שפה:Inglês
יצא לאור: 2017
נושאים:
Article
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC5712262/
https://ncbi.nlm.nih.gov/pubmed/28978636
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-17-0899
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים